According to the report by Finan, the GLP-1R/GIPR dual-agonists could provide more significant hypoglycemic, hyperlipidemic, and anti-obesity effects compared with single agonists with attenuated gastrointestinal discomfort and nausea (typically associated with GLP-1R agonists) [48]. This evidence concerns the gene GIPR and obesity disorder.